Sugi Predict

Sugi Predict / Compounds / SCHEMBL487947

SCHEMBL487947

SCHEMBL487947

Nc1ncc(-c2cccc(NS(=O)(=O)CCN3CC[C@@H](CO)C3)c2)cc1OCc1c(F)ccc(F)c1Cl

nearest known ligand 0.46

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 13/20 0.46
▸ MAP4K3 Q8IVH8 2/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ ALOX5AP P20292 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ ACVR1 Q04771 2/20 0.35
▸ RIPK2 O43353 1/20 0.35
▸ NOD2 Q9HC29 1/20 0.35
▸ FYN P06241 1/20 0.34
▸ TGFBR1 P36897 1/20 0.34
▸ MAP4K4 O95819 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452453 1.00 MET (0.46) METMAP4K3JAK2ALOX5APFEN1
SCHEMBL30453699 0.92 MET (0.47) METMAP4K3JAK2ACVR1RIPK2
SCHEMBL488155 0.92 MET (0.47) METMAP4K3JAK2ACVR1RIPK2
SCHEMBL488348 0.90 MET (0.48) METMAP4K3JAK2ACVR1RIPK2
SCHEMBL30453487 0.90 MET (0.48) METMAP4K3JAK2ACVR1RIPK2
SCHEMBL10216235 0.88 TYRO3 (0.39) METMAP4K4
SCHEMBL488117 0.88 TYRO3 (0.39) METMAP4K4
SCHEMBL30452859 0.88 TYRO3 (0.39) METMAP4K4
SCHEMBL488343 0.88 MET (0.51) METMAP4K3JAK2ACVR1RIPK2
SCHEMBL30452745 0.88 MET (0.51) METMAP4K3JAK2ACVR1RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 — — US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 — — US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 — — US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 MET 1/4885MAP4K3 8/4885JAK2 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.